Anti–B7-H3 ADCs Take Center Stage against SCLC at WCLC

IF 29.5 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2026-09-17 DOI:10.1158/2159-8290.cd-nw2026-0088

引用次数: 0

Abstract

: Separate phase III trials of the anti–B7-H3 antibody–drug conjugates tambotatug pelitecan and risvutatug rezetecan significantly improved overall survival, progression-free survival, and objective response rates compared with topotecan in patients with relapsed small-cell lung cancer. In a third trial, the combination of the investigational PD-L1 x VEGF-A bispecific antibody pumitamig plus the anti–B7-H3 ADC elfetabart drozuntecan showed encouraging early efficacy in SCLC across lines of therapy and doses. The studies were presented at the 2026 World Congress on Lung Cancer in Seoul, Republic of Korea.

查看原文本刊更多论文

抗b7 - h3 adc在WCLC中对SCLC起中心作用

与拓扑替康相比，抗b7 - h3抗体-药物偶联tambotatug pelitecan和risvutatug rezetecan在复发性小细胞肺癌患者中的总生存期、无进展生存期和客观缓解率显著提高。在第三项试验中，PD-L1 x VEGF-A双特异性抗体pumitamig与抗b7 - h3 ADC elfe他art drozuntecan的组合在SCLC的治疗和剂量方面显示出令人鼓舞的早期疗效。这些研究在韩国首尔举行的2026年世界肺癌大会上发表。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.